Cancer of the Bone and Connective Tissue

  • Mathew J. MostEmail author
  • John Haskoor


Musculoskeletal tumors may have the greatest potential to affect function. Frequently, a multidisciplinary approach with intense rehabilitation is required in this population. Histologic diagnosis generally determines treatment options for bone and soft tissue tumors. The primary goal of musculoskeletal tumor surgery is to obtain an adequate resection with negative margins to reduce the risk of local recurrence and/or distant spread. Contraindications to limb salvage include inability to preserve critical neurovascular structures due to tumor involvement that would otherwise leave a poorly or nonfunctional limb. Primary malignant bone and soft tissue tumors are far less common than metastatic disease to bone. The most common primary solid organ tumors resulting in bone metastasis are breast, lung, thyroid, kidney, prostate, and melanoma. Mechanical load of the involved area must be considered when determining precautions. Metastatic disease to bone is often treated with radiation for palliation of bone pain regardless of cancer type. Symptomatic multiple myeloma is treated by hematopoietic cell transplantation (HCT) and/or chemotherapy depending on eligibility and risk stratification.


Osteosarcoma Ewing’s sarcoma Limb salvage Multiple myeloma 


  1. 1.
    Enneking WF. Musculoskeletal tumor surgery. New York: Churchill Livingstone; 1983.Google Scholar
  2. 2.
    Katsanos K, Sabharwal T, Adam A. Percutaneous cementoplasty. Semin Intervent Radiol. 2010;27(2):137–47.CrossRefGoogle Scholar
  3. 3.
    Waters RL, Perry J, Antonelli D, Hislop H. Energy cost of walking of amputees: the influence of level of amputation. J Bone Joint Surg Am. 1976;58(1):42–6.CrossRefGoogle Scholar
  4. 4.
    Local Coverage Determination (LCD): Lower Limb Prostheses (L33787). Centers for Medicare and Medicaid Services.Google Scholar
  5. 5.
    Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584–93.CrossRefGoogle Scholar
  6. 6.
    Quinn RH, Randall RL, Benevenia J, Berven SH, Raskin KA. Contemporary management of metastatic bone disease: tips and tools of the trade for general practitioners. J Bone Joint Surg Am. 2013;95(20):1887–95.CrossRefGoogle Scholar
  7. 7.
    Greenspan A, Jundt G, Remagen W. Differential diagnosis in orthopaedic oncology. Philadelphia: Lippincott Williams & Wilkins; 2007.Google Scholar
  8. 8.
    Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989;249:256–64.Google Scholar
  9. 9.
    Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol Ther. 2016;3(2):221–43. Epub 2016 Oct 19.CrossRefGoogle Scholar
  10. 10.
    Ozaki T. Diagnosis and treatment of Ewing sarcoma of the bone: a review article. J Orthop Sci. 2015;20(2):250–63.CrossRefGoogle Scholar
  11. 11.
    Kridis WB, Toumi N, Chaari H, et al. A review of Ewing sarcoma treatment: is it still a subject of debate? Rev Recent Clin Trials. 2017;12(1):19–23.CrossRefGoogle Scholar
  12. 12.
    Nassif NA, Tseng W, Borges C, Chen P, Eisenberg B. Recent advances in the management of liposarcoma. F1000Res. 2016;5:2907.CrossRefGoogle Scholar
  13. 13.
    Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320–9.CrossRefGoogle Scholar
  14. 14.
    Egas-bejar D, Huh WW. Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolesc Health Med Ther. 2014;5:115–25.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Stacchiotti S, Van Tine BA. Synovial sarcoma: current concepts and future perspectives. J Clin Oncol. 2018;36(2):180–7.CrossRefGoogle Scholar
  16. 16.
    Hakim DN, Pelly T, Kulendran M, Caris JA. Benign tumours of the bone: a review. J Bone Oncol. 2015;4(2):37–41.CrossRefGoogle Scholar
  17. 17.
    Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant cell tumor of bone – an overview. Arch Bone Joint Surg. 2016;4(1):2–9.PubMedGoogle Scholar
  18. 18.
    Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol. 2013;20(5):e442–7.CrossRefGoogle Scholar
  19. 19.
    Roberts CC, et al. ACR appropriateness criteria on metastatic bone disease. J Am College Radiol. 2010;7(6):400–9.CrossRefGoogle Scholar
  20. 20.
    Mitin T, Loeffler JS, Vora SR. Radiation therapy techniques in cancer treatment. Last updated 1 Aug 2017.
  21. 21.
    Rajkumar SV, Kyle RA, Connor RF. Overview of the management of multiple myeloma. Last updated 19 July 2018.
  22. 22.
    Stubblefield MD. Neuromuscular complications of radiation therapy. Muscle Nerve. 2017;56(6):1031–40.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Orthopedic Oncology, Department of Orthopedics and Physical RehabilitationUMass Memorial HealthCareWorcesterUSA
  2. 2.Department of Orthopedics and Physical RehabilitationUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations